Table 2.

NVG patient backgrounds according to treatment received. The majority of patients in the LEC group had stage 3 NVG and had previously received other treatments, such as adequate PRP, stand-alone anti-VEGF therapy, and PPV. Approximately half (41.2%) of patients that received frequent stand-alone anti-VEGF treatment had previously received repeated anti-VEGF injections.

Treatments	Anti-VEGF stand-alone therapy	Additional PRP	PPV	LEC
Number of treatments	17	89	28	32
Anti-VEGF combination therapy (n)	—	49	15	3
Pre-treatment IOP (mmHg)	36.1 ± 12.5	36.1 ± 13.5	33.7 ± 13.9	35.0 ± 8.1
Criteria
Rubeosis group	1 (5.9%)	9 (10.1%)	4 (14.3%)	1 (3.1%)
Open-angle NVG group	10 (58.8%)	51 (57.3%)	12 (42.9%)	8 (25.0%)
Angle-closure NVG group	6 (35.3%)	12 (32.6%)	12 (42.9%)	23 (71.9%)∗
Previous treatment
Anti-VEGF stand-alone therapy	7 (41.2%)∗	1 (1.1%)	3 (10.7%)†	23 (71.9%)∗
PRP	17 (100.0%)∗	(44.9%)	(85.7%)	32 (100.0%)∗
PPV	4 (23.5%)	0 (0%)	0 (0%)	7 (21.9%)
LEC	1 (5.9%)	0 (0%)	0 (0%)	1 (3.1%)
Follow-up   (pre-treatment, months)	2.5 ± 2.8∗  0.0 to 8.3	0.8 ± 3.0  0.0 to 22.3	3.2 ± 7.9∗  1.0 to 33.3	7.2 ± 11.5∗  0.0 to 48.8
Follow-up   (post-treatment, months)	21.0 ± 19.7  4.1–53.2	25.4 ± 21.6  4.0–81.8	25.0 ± 14.3  5.1–56.0	24.5 ± 22.6  4.3–60.7

PRP, panretinal laser photocoagulation; PPV, pars plana vitrectomy, LEC, trabeculectomy with mitomycin C.

Mean ± SD, Steel-Dwass test ^∗ P < 0.05 for PDR, ^† P < 0.05 for OIS.